消化指南

订阅

MedSci主页 / 所有栏目 / 消化指南

2019 WSES指南：急性重症胰腺炎的管理

2019-06-13 世界急诊外科学会 World J Emerg Surg. 2019 Jun 13;14:27.

急性重症胰腺炎

2019年6月，世界急诊外科学会(WSES)发布了急性重症胰腺炎的管理指南。尽管多数胰腺炎患者都为轻度胰腺炎，但约有20%~30%的患者可进展为重症疾病，这通常与单个或多个器官功能障碍有关，需要重症监护。本文主要针对急性重症胰腺炎的管理提出指导建议，内容涉及诊断，抗生素预防，重症监护管理，手术以及围术期管理等。

中文标题：

2019 WSES指南：急性重症胰腺炎的管理

英文标题：

2019 WSES guidelines for the management of severe acute pancreatitis.

发布机构：

世界急诊外科学会

发布日期：

2019-06-13

简要介绍：

2019年6月，世界急诊外科学会(WSES)发布了急性重症胰腺炎的管理指南。尽管多数胰腺炎患者都为轻度胰腺炎，但约有20%~30%的患者可进展为重症疾病，这通常与单个或多个器官功能障碍有关，需要重症监护。本文主要针对急性重症胰腺炎的管理提出指导建议，内容涉及诊断，抗生素预防，重症监护管理，手术以及围术期管理等。 

拓展指南：与胰腺炎相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2019 WSES指南：急性重症胰腺炎的管理)] GetToolGuiderByIdResponse(projectId=1, id=7fe7e1c001e52761, title=2019 WSES指南：急性重症胰腺炎的管理, enTitle=2019 WSES guidelines for the management of severe acute pancreatitis., guiderFrom=World J Emerg Surg. 2019 Jun 13;14:27., authorId=null, author=, summary=2019年6月，世界急诊外科学会(WSES)发布了急性重症胰腺炎的管理指南。尽管多数胰腺炎患者都为轻度胰腺炎，但约有20%~30%的患者可进展为重症疾病，这通常与单个或多个器官功能障碍有关，需要重症监护。本文主要针对急性重症胰腺炎的管理提出指导建议，内容涉及诊断，抗生素预防，重症监护管理，手术以及围术期管理等。 , cover=, journalId=null, articlesId=null, associationId=1090, associationName=世界急诊外科学会, associationIntro=null, copyright=0, guiderPublishedTime=Thu Jun 13 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<div>2019年6月，世界急诊外科学会(WSES)发布了急性重症胰腺炎的管理指南。尽管多数胰腺炎患者都为轻度胰腺炎，但约有20%~30%的患者可进展为重症疾病，这通常与单个或多个器官功能障碍有关，需要重症监护。本文主要针对急性重症胰腺炎的管理提出指导建议，内容涉及诊断，抗生素预防，重症监护管理，手术以及围术期管理等。 </div> <div><br> </div>拓展指南：<strong>与<font color=red>胰腺炎</font>相关指南：</strong><br><ul><li><a href="https://www.medsci.cn/guideline/show_article.do?id=eb3621c0016931c4" title="2018 ESGE指南：慢性胰腺炎的内镜治疗" target=_blank>2018 ESGE指南：慢性胰腺炎的内镜治疗</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=86d0d1c001638313" title="2018 IAP/APA/JPS/EPC指南：慢性胰腺炎截面影像学诊断和严重程度评分" target=_blank>2018 IAP/APA/JPS/EPC指南：慢性胰腺炎截面影像学诊断和严重程度评分</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=554e41c00163e59d" title="2018 NICE指南：胰腺炎（NG.104）" target=_blank>2018 NICE指南：胰腺炎（NG.104）</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=5c0b21c001629585" title="2018 儿童时期自身免疫性胰腺炎的诊断和管理建议" target=_blank>2018 儿童时期自身免疫性胰腺炎的诊断和管理建议</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=6465b1c0016266eb" title="《2018年早期慢性胰腺炎国际共识声明》摘译" target=_blank>《2018年早期慢性胰腺炎国际共识声明》摘译</a></li> 更多信息请点击：<a href="https://www.medsci.cn/guideline/list.do?q=%E8%83%B0%E8%85%BA%E7%82%8E" target=_blank>有关胰腺炎更多指南</a></ul>, tagList=[TagDto(tagId=91444, tagName=急性重症胰腺炎)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=91, categoryName=肝胆胰外科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=8676, appHits=1166, showAppHits=7, pcHits=4634, showPcHits=4231, likes=101, shares=41, comments=21, approvalStatus=1, publishedTime=Tue Jun 25 21:13:56 CST 2019, publishedTimeString=2019-06-13, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Tue Jun 25 21:13:56 CST 2019, updatedBy=null, updatedName=null, updatedTime=Thu Jan 04 22:07:29 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2019 WSES指南：急性重症胰腺炎的管理)])
2019 WSES指南：急性重症胰腺炎的管理
下载请点击：
评论区 (14)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2175088, encodeId=f29821e5088de, content=内容丰富, beContent=null, objectType=guider, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be6a2227371, createdName=12116ff9m13(暂无昵称), createdTime=Fri Dec 15 13:39:50 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1192455, encodeId=9a511192455ad, content=拓展指南这个形式不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b5d3045764, createdName=729787690, createdTime=Fri Feb 11 21:03:00 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966590, encodeId=a10196659091, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c693578928, createdName=132c6090m78暂无昵称, createdTime=Tue May 18 14:57:45 CST 2021, time=2021-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959693, encodeId=c2d8959693b5, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/972f8c2f32a64cd28f904bad3945efc9/3d1556a9e54b4781a5f4968d888e5874.jpg, createdBy=5d015401562, createdName=海明明, createdTime=Fri Apr 23 09:55:07 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946229, encodeId=a5719462297a, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0445463981, createdName=ms8000001782214256, createdTime=Sun Mar 07 19:43:02 CST 2021, time=2021-03-07, status=1, ipAttribution=)]
    2023-12-15 12116ff9m13(暂无昵称) 来自北京

    内容丰富

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2175088, encodeId=f29821e5088de, content=内容丰富, beContent=null, objectType=guider, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be6a2227371, createdName=12116ff9m13(暂无昵称), createdTime=Fri Dec 15 13:39:50 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1192455, encodeId=9a511192455ad, content=拓展指南这个形式不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b5d3045764, createdName=729787690, createdTime=Fri Feb 11 21:03:00 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966590, encodeId=a10196659091, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c693578928, createdName=132c6090m78暂无昵称, createdTime=Tue May 18 14:57:45 CST 2021, time=2021-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959693, encodeId=c2d8959693b5, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/972f8c2f32a64cd28f904bad3945efc9/3d1556a9e54b4781a5f4968d888e5874.jpg, createdBy=5d015401562, createdName=海明明, createdTime=Fri Apr 23 09:55:07 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946229, encodeId=a5719462297a, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0445463981, createdName=ms8000001782214256, createdTime=Sun Mar 07 19:43:02 CST 2021, time=2021-03-07, status=1, ipAttribution=)]
    2022-02-11 729787690

    拓展指南这个形式不错

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2175088, encodeId=f29821e5088de, content=内容丰富, beContent=null, objectType=guider, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be6a2227371, createdName=12116ff9m13(暂无昵称), createdTime=Fri Dec 15 13:39:50 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1192455, encodeId=9a511192455ad, content=拓展指南这个形式不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b5d3045764, createdName=729787690, createdTime=Fri Feb 11 21:03:00 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966590, encodeId=a10196659091, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c693578928, createdName=132c6090m78暂无昵称, createdTime=Tue May 18 14:57:45 CST 2021, time=2021-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959693, encodeId=c2d8959693b5, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/972f8c2f32a64cd28f904bad3945efc9/3d1556a9e54b4781a5f4968d888e5874.jpg, createdBy=5d015401562, createdName=海明明, createdTime=Fri Apr 23 09:55:07 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946229, encodeId=a5719462297a, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0445463981, createdName=ms8000001782214256, createdTime=Sun Mar 07 19:43:02 CST 2021, time=2021-03-07, status=1, ipAttribution=)]
    2021-05-18 132c6090m78暂无昵称

    学习学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2175088, encodeId=f29821e5088de, content=内容丰富, beContent=null, objectType=guider, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be6a2227371, createdName=12116ff9m13(暂无昵称), createdTime=Fri Dec 15 13:39:50 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1192455, encodeId=9a511192455ad, content=拓展指南这个形式不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b5d3045764, createdName=729787690, createdTime=Fri Feb 11 21:03:00 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966590, encodeId=a10196659091, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c693578928, createdName=132c6090m78暂无昵称, createdTime=Tue May 18 14:57:45 CST 2021, time=2021-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959693, encodeId=c2d8959693b5, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/972f8c2f32a64cd28f904bad3945efc9/3d1556a9e54b4781a5f4968d888e5874.jpg, createdBy=5d015401562, createdName=海明明, createdTime=Fri Apr 23 09:55:07 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946229, encodeId=a5719462297a, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0445463981, createdName=ms8000001782214256, createdTime=Sun Mar 07 19:43:02 CST 2021, time=2021-03-07, status=1, ipAttribution=)]
    2021-04-23 海明明

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2175088, encodeId=f29821e5088de, content=内容丰富, beContent=null, objectType=guider, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be6a2227371, createdName=12116ff9m13(暂无昵称), createdTime=Fri Dec 15 13:39:50 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1192455, encodeId=9a511192455ad, content=拓展指南这个形式不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b5d3045764, createdName=729787690, createdTime=Fri Feb 11 21:03:00 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966590, encodeId=a10196659091, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c693578928, createdName=132c6090m78暂无昵称, createdTime=Tue May 18 14:57:45 CST 2021, time=2021-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959693, encodeId=c2d8959693b5, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/972f8c2f32a64cd28f904bad3945efc9/3d1556a9e54b4781a5f4968d888e5874.jpg, createdBy=5d015401562, createdName=海明明, createdTime=Fri Apr 23 09:55:07 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946229, encodeId=a5719462297a, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0445463981, createdName=ms8000001782214256, createdTime=Sun Mar 07 19:43:02 CST 2021, time=2021-03-07, status=1, ipAttribution=)]
    2021-03-07 ms8000001782214256

    好

    0

以上为热门评论，梅斯医学App还有更多内容